West Pharmaceutical Services (WST) Operating Margin (2009 - 2026)

West Pharmaceutical Services has disclosed Operating Margin across 18 years of filings, most recently posting 20.96% for Q1 2026.

• Operating Margin for Q1 2026 came in at 20.96%, up 563.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 20.34% (up 120.0% YoY), and the FY2025 annual result was 19.03%, down 67.0% from the prior year.
• Operating Margin came in at 20.96% for Q1 2026 at West Pharmaceutical Services, up from 19.45% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 29.61% in Q2 2022 to a low of 15.33% in Q1 2025.
• The 5-year median for Operating Margin is 21.31% (2024), against an average of 21.65%.
• Across the five-year window, Operating Margin sank 688 bps in 2022 and surged 563 bps in 2026, its largest moves.
• West Pharmaceutical Services' Operating Margin stood at 18.3% in 2022, then gained by 20 bps to 21.98% in 2023, then retreated by 3 bps to 21.31% in 2024, then dropped by 9 bps to 19.45% in 2025, then gained by 8 bps to 20.96% in 2026.
• The last three Operating Margin figures came in at 20.96% (Q1 2026), 19.45% (Q4 2025), and 20.83% (Q3 2025), per Business Quant data.